Peptinovo Biopharma, a biotechnology company pioneering targeted cancer therapies through its proprietary PALM nanotechnology, has announced a strategic manufacturing partnership with Ardena, a specialist pharmaceutical contract development and manufacturing organization (CDMO) and bioanalytical contract research organization (CRO) enabling precision medicines and other complex therapies. Ardena will manufacture Peptinovo’s cancer drug-delivery nanotechnology for the company’s planned launch of ...